Pulmonx Corporation
Clinical trials sponsored by Pulmonx Corporation, explained in plain language.
Develops minimally invasive treatments for chronic obstructive pulmonary disease.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- One-Way valves in the lung: can they help emphysema patients breathe easier? Results expected Dec 2026 (estimated)
- Tiny One-Way valves for emphysema under close watch in japan Results expected Mar 2027 (estimated)
- Foam plug could open door to lung valve therapy for thousands Results expected Jun 2027 (estimated)
-
Foam plug could open door to lung valve therapy for thousands
Disease control Recruiting nowThis study tests a foam called AeriSeal that is squirted into damaged parts of the lung to block tiny air leaks. After the foam, doctors check if the lung is now sealed enough to place a one-way valve that lets trapped air escape. The goal is to help people with severe emphysema …
Sponsor: Pulmonx Corporation • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Tiny One-Way valves for emphysema under close watch in japan
Symptom relief Recruiting nowResearchers in Japan are observing 140 people with severe emphysema who receive Zephyr Endobronchial Valves, tiny one-way valves placed in the lungs to reduce hyperinflation. The surveillance follows participants for 12 months across up to 20 centers. The main goal is to measure …
Sponsor: Pulmonx Corporation • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC